Stifel starts coverage of Immatics stock with USD 15 target

Published on 10/18/2026 at 13:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stifel set a USD 15.00 target on October 13, 2026 for Immatics stock. Second-quarter revenue was USD 9.14 million.

Analyst view and reporting date

Stifel began coverage with a USD 15.00 target on October 13, 2026.
Immatics reported USD 9.14 million in second-quarter 2026 revenue and a USD 0.46 loss per share.
The next reporting date is November 17, 2026.

IMTX, NL0015285941, Illustration mit AI erstellt.

Immatics N.V. (NL0015285941) drew a new analyst view on October 13, 2026, when Stifel began coverage with a Buy rating and a USD 15.00 price target. The note tied that view to the companys PRAME-HLA directed cell therapy anzu-cel and its melanoma development plans, as Markets Insider reported.

Three milestones shape the story

The recent sequence starts with Immatics reporting second-quarter 2026 revenue of USD 9.14 million and a loss of USD 0.46 per diluted share on August 18, 2026. The figures came from the companys quarter ended June 30, 2026, and were carried by Nasdaq.

On August 25, 2026, Jefferies held a USD 17.00 target in the analyst history summarized by MarketBeat. Stifels newer USD 15.00 target is therefore below that earlier target, while still standing above the USD 6.73 Nasdaq quote last reported for October 16, 2026.

What does the target mean?

The target highlights the gap between clinical ambition and present operating results. Stifel modeled global sales of USD 1.27 billion by 2035 for two melanoma assets, while Immatics remained in clinical development and reported a USD 62.49 million net loss for the second quarter of 2026. That contrast makes trial execution and financing capacity central to the investment case.

Next reporting date

TradingView lists November 17, 2026 as the next earnings date for Immatics. The companys pipeline centers on T-cell receptor therapies and TCR bispecifics, with PRAME targeting forming a central part of its stated strategy.

Market context stays clinical

On Nasdaq, the stock was last at USD 6.73 on October 16, 2026 at 4:00 p.m. ET. The finance snapshot places its market capitalization at USD 1.0 billion and its 52-week range at USD 6.65 to USD 12.41 as of October 16, 2026. The further course of trading is shown by the continuously updated real-time quote of Immatics stock.